Management of myelofibrosis after ruxolitinib failure

Bose, P; Verstovsek, S

Bose, P (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1400 Holcombe Blvd,Unit 428,FC4-3062, Houston, TX 77030 USA.

LEUKEMIA & LYMPHOMA, 2020; 61 (8): 1797

Abstract

Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management. Ruxolitinib im......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索